Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otilimab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ontamalimab, an antibody targeting MADCAM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Birtamimab, an antibody targeting SAA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Upinitatug, an antibody targeting SLC34A2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabatolimab, an antibody targeting TIM-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tusamitamab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briakinumab, an antibody targeting IL-12/23p40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Maftivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Edrecolomab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Arcitumomab, an antibody targeting CEA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abciximab, an antibody targeting ITGA2B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Basiliximab, an antibody targeting IL2RA.